Superseded public profile

In clinical trials↗↗Metabolic↗

Superseded · version 3: Amycretin↗

Related names recorded in this version: Zenagamtide↗↗

An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, published trial results from our human evidence review, and the 2026 report that renames amycretin zenagamtide. 24

What this version reported

Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.↗↗↗

Organizations named in cited records:
  • Novo Nordisk A/S↗

Trial records: NCT06049329

Reader guide in this version

Key takeaway

Amycretin, now named zenagamtide, is an experimental Novo Nordisk peptide that activates the receptors for GLP-1 and amylin, two hormones involved in appetite and blood sugar.1,4 It is not FDA-approved. The sources reviewed here describe it only in clinical trials, and none reports an approval in any country.1,4 Published randomized trials report weight loss in early studies and lower blood sugar in a Phase 2 diabetes trial, with common gastrointestinal side effects. Each trial had fewer than 300 participants.2,3,4

At a glance

What it is
An investigational single-molecule agonist of the GLP-1 and amylin receptors from Novo Nordisk. The 2026 Phase 2 report names it zenagamtide (formerly amycretin) and says it also acts on calcitonin receptors.1,4
FDA status
Not FDA-approved. The sources reviewed here describe it only in clinical trials sponsored by Novo Nordisk.1,4
Human evidence
Smaller randomized, placebo-controlled trials: two early trials in adults with overweight or obesity and a Phase 2 trial in type 2 diabetes.2,3,4
Evidence strength
Smaller controlled human trials

What is amycretin?

Amycretin is an experimental drug being developed by Novo Nordisk, which ClinicalTrials.gov lists as the sponsor of the trial record cited on this profile.1

A 2026 Lancet report describes zenagamtide, formerly amycretin, as a single molecule that activates the receptors for GLP-1, amylin and calcitonin.4

How is amycretin thought to work?

The published trial reports describe amycretin as a unimolecular GLP-1 and amylin receptor agonist, meaning one molecule designed to mimic two hormones that help regulate appetite and blood sugar.2,3

The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.2,4

What do human studies show?

A first-in-human randomized, placebo-controlled trial in 144 adults with overweight or obesity was designed mainly to assess safety. Adverse events were mild or moderate, and gastrointestinal events were common.2

In a randomized Phase 1b/2a trial in 125 adults with overweight or obesity lasting up to 36 weeks, estimated weight reductions were greater with amycretin than placebo; gastrointestinal events were common and many participants withdrew.3

In a 36-week randomized, placebo-controlled Phase 2 trial in 262 adults with type 2 diabetes, HbA1c, a measure of long-term blood sugar, improved more with the drug than with placebo. Gastrointestinal adverse events were common.4

These were short trials with mostly safety or blood-sugar outcomes, and they do not show long-term benefits or rare harms.2,3,4

What the evidence base contains

  • Controlled human trial A first-in-human, double-blind, randomized, placebo-controlled Phase 1 trial in 144 adults with overweight or obesity, designed mainly to assess safety.2
  • Controlled human trial A randomized, placebo-controlled Phase 1b/2a trial in 125 adults with overweight or obesity at one research center, lasting up to 36 weeks.3
  • Controlled human trial A 36-week double-blind, randomized, placebo-controlled Phase 2 trial in which 262 adults with type 2 diabetes were randomized, published in The Lancet in 2026.4

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is amycretin FDA-approved?

No. Amycretin remains in clinical trials. None of the sources reviewed here reports an approval of amycretin or zenagamtide in any country.1,4

A Novo Nordisk trial in Japanese men with obesity is listed on ClinicalTrials.gov as completed, in a record last updated on March 5, 2025.1

The 2026 Phase 2 report was published under the name zenagamtide and describes it as formerly amycretin.4

Timeline

  1. Results of the first two randomized amycretin trials are published in The Lancet.2,3
  2. ClinicalTrials.gov updates the record of a completed Novo Nordisk amycretin trial in Japanese men.1
  3. Results of a Phase 2 trial in type 2 diabetes are published under the name zenagamtide.4

What is still unknown?

Whether its effects on weight and blood sugar hold up in larger, longer trials: the published trials lasted up to 36 weeks and had fewer than 300 participants each.2,3,4

Its long-term safety and effects on outcomes such as heart disease, which the published trials did not measure.2,3,4

Sources for this version

  1. 1
    Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  2. 2
    Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial (2025) · PMID 40550229 ↗

    The Lancet · Official source · Source checked November 14, 2026

  3. 3
    Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (2025) · PMID 40550231 ↗

    The Lancet · Official source · Source checked November 14, 2026

  4. 4
    Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (2026) · PMID 42532080 ↗

    The Lancet · Official source · Source checked November 14, 2026